NEW YORK (GenomeWeb News) – Molecular diagnostics firm Provista Diagnostics today announced the completion of a Series B financing round that raised $6 million.

Existing investors participated in the round, which will be used to expand the company's commercial market development of dtectDx-Breast as Provista pursues 510(k) clearance of the assay. The firm also plans to conduct additional clinical trials for the test, which detects blood-based protein biomarkers that are "highly associated" with the development of breast cancer, it said on its website.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

NPR reports that Turkish high school students will no longer study evolution.

Researchers report they sequenced and identified plant species in an "al fresco" laboratory.

An Australian team searches for genetic alterations linked to depression in hopes of developing personalized treatments, the Sydney Morning Herald reports.

In PNAS this week: host contributors to typhoid fever risk, effects of obesity-related variants near TMEM18, and more.

Oct
10
Sponsored by
PerkinElmer

This online, interactive seminar will answer researchers’ most pressing questions about how to gain outstanding research results from proteomic studies.